We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genes Should Be Screened for Stem Cell Transplants

By LabMedica International staff writers
Posted on 10 May 2017
Regenerative medicine using human pluripotent stem cells (hPS cells) to grow transplantable tissue outside the body carries the promise to treat a range of intractable disorders, such as diabetes and Parkinson's disease. More...
These hPS cells can self-renew indefinitely, making them an attractive source for regenerative therapies.

As stem cell lines grow in a laboratory dish, they often acquire mutations in the Tumor Protein P53 (p53) gene, an important tumor suppressor responsible for controlling cell growth. It is suggested that genetic sequencing technologies should be used to screen for mutated cells in stem cell cultures, so that cultures with mutated cells can be excluded from therapeutic use.

An international team of scientists working with a group at Harvard University sequenced the protein-coding genes (exomes) of 140 independent human embryonic stem cell (hES cell) lines, including 26 lines prepared for potential clinical use. They then apply computational strategies for identifying mutations present in a subset of cells in each hES cell line.

They identified five unrelated hES cell lines that carried six mutations in the TP53 gene that encodes the tumor suppressor P53. The TP53 mutations we observed are dominant negative and are the mutations most commonly seen in human cancers. They found that the TP53 mutant allelic fraction increased with passage number under standard culture conditions, suggesting that the P53 mutations confer selective advantage. They performed a sophisticated set of DNA analyses to rule out the possibility that these mutations had been inherited rather than acquired as the cells grew in the lab. The scientists found that P53 mutant cells outperformed and surpassed non-mutant cells in the laboratory. In other words, a culture with a million healthy cells and one p53 mutant cell could quickly become a culture of only mutant cells.

The authors concluded that as the acquisition and expansion of cancer-associated mutations in hPS cells may go unnoticed during most applications, they suggest that careful genetic characterization of hPS cells and their differentiated derivatives be carried out before clinical use. Kevin C. Eggan, PhD, the principal investigator said, “Our findings indicate that an additional series of quality control checks should be implemented during the production of stem cells and their downstream use in developing therapies. Fortunately, these genetic checks can be readily performed with precise, sensitive, and increasingly inexpensive sequencing methods.” The study was published on April 26, 2017, in the journal Nature.


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.